← All trials
NCT04158713
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 7, 2019
- Primary completion
- Feb 1, 2021
- Completion date
- Nov 30, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 898
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LiverpoolLead sponsor
- University of MassachusettsCollaborator
- University of MalawiCollaborator
- University of TorontoCollaborator
- Centers for Disease Control and Prevention (CDC)Collaborator
- University of LiverpoolOverall official - principal investigator
- Kenya Medical Research InstituteCollaborator
- University of CopenhagenCollaborator
- University of MelbourneCollaborator
- Banook GroupCollaborator
- University of Cape TownCollaborator
- Wellcome TrustCollaborator
- Kenya National AIDS & STI Control ProgrammeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.